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Abstract
We demonstrate the synergistic antitumor effect of oridonin and the PI3K/mTOR inhibitor NVP-BEZ235 on the
non-germinal center B cell-like subtype of diffuse large B cell lymphoma (non-GCB DLBCL) both in vitro and in
vivo. The underlying mechanism may be multifunctional, involving apoptosis, AKT/mTOR and NF-kB inactivation, and
ROS-mediated DNA damage response. Our findings pave the way for a new potential treatment option for non-GCB
DLBCL with the combination of oridonin and NVP-BEZ235.
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Findings
Diffuse large B cell lymphoma (DLBCL) is the most
common aggressive form of non-Hodgkin’s lymphoma
(NHL) in adults, and it can be distinguished into two
major groups, the germinal center B cell (GCB) subtype
and the non-germinal center B cell-like (non-GCB)
subtype [1, 2]. The non-germinal center B cell-like sub-
type of diffuse large B cell lymphoma (non-GCB DLBCL)
presents aggressive clinical courses and poor prognosis [3,
4]. Targeting key pathways may raise the possibility of
improving clinical outcomes.
Our previous studies have indicated that oridonin and
NVP-BEZ235 have some antitumor effects in DLBCL
cells [5, 6]. The aim of this study was to determine
whether oridonin combined with NVP-BEZ235 could
achieve a more significant antitumor effect on the non-
GCB DLBCL, and to further investigate the underlying
mechanism. The materials and methods used in this
study are detailed in Additional file 1.
Our results demonstrate that oridonin and NVP-BEZ235
exhibit a synergistic effect on non-GCB DLBCL cell lines
(OCI-Ly3 and SU-DHL-2), and the co-treatment was more
effective on cell proliferation inhibition compared with
single-agent therapy (Additional file 2). And then cytotoxic
effect of oridonin and NVP-BEZ235 alone or in combi-
nation were evaluated in nude mice bearing SU-DHL-2 tu-
mors. Compared with the control group or single-agent
group, the co-treatment group exhibited more significant
DLBCL cell growth inhibition in terms of tumor size
(Fig. 1a) and weight (Fig. 1d) and prolonged the mice
survival (Fig. 1b). H&E staining and TUNEL assay showed
that co-treatment with oridonin and NVP-BEZ235 obvi-
ously increased apoptosis (Fig. 1c, e).
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To explore the mechanism underlying the synergistic
antitumor effect, both cell lines were exposed to 2 μM
oridonin and 25 nM NVP-BEZ235 alone or in combi-
nation for 24 and 48 h. The results showed that the co-
treatment induced higher apoptosis in non-GCB DLBCL
cell lines (Fig. 2a, b). Meanwhile, the apoptosis induced
by the drug combination was further confirmed by
assessment of caspase family and Bcl-2 family protein
expression (Additional file 3). However, co-treatment
does not further enhance cell-cycle arrest in G0/G1
phase (Additional file 4).
To further investigate the mechanism of synergistic
drug effects, the expression of AKT/mTOR and NF-kB
pathway was assessed by western blotting. The data
suggest that the simultaneous inhibition of the PI3K/
AKT/mTOR and NF-kB pathways abrogated the key
survival signals for non-GCB DLBCL, which might in-
dicate the mechanism for the synergistic pro-apoptotic
effect of oridonin and NVP-BEZ235 in combination
(Fig. 2c, d). We then found that oridonin and NVP-
BEZ235 in combination markedly induced the expression
of γH2AX, a marker of DNA damage. Flow cytometry also
Fig. 1 Oridonin combined with NVP-BEZ235 dramatically inhibited tumor growth and prolonged the survival in a non-GCB DLBCL xenograft
mouse model (SU-DHL-2). a, d Mice in each cohort were treated with oridonin (5 mg/kg) and NVP-BEZ235 (20 mg/kg) alone or in combination
every other day. Tumor volumes were measured once every 4 days. After 32 days, the mice were sacrificed, and the tumors were removed and
weighed. b Overall survival was prolonged by oridonin and NVP-BEZ235 combination therapy compared with the control group and single-agent
group (p < 0.005). c HE staining and TUNEL assay was performed to examine the apoptosis in tumor tissues. e Bar graph illustrate the proportion
of positive cells showed in TUNEL assay. *p < 0.05, **p <0.01, ***p < 0.001 compared with the control group; #p < 0. 05, ##p < 0.01 compared with
single-agent group
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demonstrated a significant increase in reactive oxygen
species (ROS) (Fig. 2e, f ). Addition of N-acetyl-L-cysteine
(NAC) largely reversed co-treatment-induced apoptosis,
while treating the cells with Z-DEVD-FMK (caspase 3
inhibitor) had little effect (Fig. 2g, Additional file 5).
Taken together, our findings demonstrated the synergistic
antitumor effect of oridonin combined with NVP-BEZ235
in non-GCB DLBCL cell lines. The potential molecular
mechanism might be multifunctional, involving apoptosis,
AKT/mTOR and NF-kB inactivation, and ROS-mediated
DNA damage response. Moreover, co-treatment was also
effective in a non-GCB DLBCL xenograft model. Therefore,
our study provides a theoretical basis and preclinical evi-
dence for this novel strategy and suggests that the combin-
ation of oridonin and NVP-BEZ235 might have promising
therapeutic application in non-GCB DLBCL patients.
Fig. 2 The mechanism of synergistic antitumor effect of oridonin and NVP-BEZ235 on non-GCB DLBCL. a, b Cell lines were treated with oridonin
(2 μM) and NVP-BEZ235 (25 nM) alone or in combination for 24 and 48 h, analyzing apoptosis by Annexin-V/PI staining. c Cell lines were treated
with oridonin (2 μM) and NVP-BEZ235 (25 nM) alone or in combination for 48 h. Western blot analysis was performed to identify the expression
of total AKT, p-AKT (Ser473), p-AKT (Thr308), mTOR, and p-mTOR. d Western blot for NF-kB, p-NF-kB, IkBα, and p-IkBα. e The expression of γH2AX
and H2AX was analyzed by western blotting. f Cell lines were simultaneously treated with oridonin (2 μM) and NVP-BEZ235 (25 nM) for 48 h, and
FACS quantitative analysis of DCF-DA was used to detect the expression of ROS. g Pretreatment of co-treatment group cells with NAC (5 mM)
and Z-DEVD-FMK (10 μM), respectively, for 48 h, analyzing apoptosis by Annexin-V/PI staining with t test statistic assay. (Mean ± SD, n = 3,
*p < 0.05, **p < 0.01 compared with Ori + BEZ group. Z: Z-DEVD-FMK)
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Additional files
Additional file 1: Materials and methods. (PDF 106 kb)
Additional file 2: Combination effects of oridonin and NVP-BEZ235 on
proliferation inhibition. (A) Cell viability of OCI-Ly3, SU-DHL-2 was measured
by CCK-8 assay after treated with oridonin (2 μM) and NVP-BEZ235 (25 nM)
alone or in combination for 48 h. Drugs were conducted simultaneously at
the indicated concentrations. (B) Isobologram analysis of agent combination
at ED50 and CI values were calculated as well. (C) CI values of all cell lines at
ED25, ED50, ED75, and ED90. The lower CI values indicated the stronger
synergism when CI < 1, and higher CI values means the stronger antagonism
when CI > 1. Additive effect was designated with CI = 1. (PDF 229 kb)
Additional file 3: Oridonin combined with NVP-BEZ235 significantly
increased the apoptosis on non-GCB DLBCL cell lines. (A, B) Cell lines
were simultaneously treated with oridonin (2 μM) and NVP-BEZ235
(25 nM) for 24 and 48 h, analyzing apoptosis by Annexin-V/PI staining
with t test statistic assay. (Mean ± SD, n = 3, *p < 0.05, **p < 0.01, ***p < 0.001
compared with control group; #p < 0. 05, ##p < 0.01 compared with single
agent group. (C) Cell lines were subjected to indicate treatments and
protein lysates were performed with immunoblotting, incubating with
PARP, caspase3, caspase9, cleaved-PARP, cleaved-caspase3, cleaved-
caspase9, Bax and Bcl-2 antibodies. (PDF 191 kb)
Additional file 4: The effect of oridonin and NVP-BEZ235 on cell cycle.
(A) Cells were treated with drugs for 48 h with the dosages indicated in
Fig 2. Cell cycle assay was assessed with cytometry and Modfit LT. The
percentage of G0 and G1phase cells is respectively shown in the left
bottom and left top corner of each panel. (B) The number of G0/G1 cells
was determined using quantitative FACS analysis. Each column represents
the mean ± SD (n = 3). Statistical analysis was performed using the
Student’s t test. NS not significant; *p < 0.05, **p < 0.01 compared with
the control group. (PDF 295 kb)
Additional file 5: Co-treatment triggered ROS generation which mediated
non-GCB DLBCL cell apoptosis. (A) Cell lines were simultaneously treated with
oridonin (2 μM) and NVP-BEZ235 (25 nM) for 48 h, FACS quantitative analysis
of DCF-DA was used to detect ROS with t test statistic assay. (Mean ± SD, n=
3, *p< 0.05, **p< 0.01 compared with control group. (B) NAC pretreatment
attenuated co-treatment-induced protein expression levels of γH2AX, cleaved-
caspase 3 and cleaved-caspase 9. (C) Pretreatment of co-treatment group cells
with NAC (5 mM) and Z-DEVD-FMK (10 μM), respectively, for 48 h, analyzing
apoptosis by Annexin-V/PI staining. (PDF 404 kb)
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